Src-dependent phosphorylation at Y406 on the thyroid hormone receptor β confers the tumor suppressor activity

Area of Science:

• Endocrinology
• Molecular Biology
• Oncology

Background:

• Thyroid hormone receptor β1 (TRβ1) is implicated as a potential tumor suppressor in cancer.
• The precise molecular mechanisms underlying TRβ1's tumor-suppressive role, particularly in breast cancer, require further elucidation.

Purpose of the Study:

• To investigate the molecular mechanisms by which TRβ1 functions as a tumor suppressor in breast cancer MDA cells.
• To determine the role of cSrc-mediated phosphorylation at Y406 in TRβ1's function and stability.

Main Methods:

• Stable expression of TRβ1 and a Y406F mutant (TRβ1Y406F) in MDA breast cancer cells.
• Assessment of cell proliferation and invasion assays.
• Analysis of TRβ1 degradation, T3 binding affinity, and cSrc association.
• Xenograft mouse models to evaluate tumor growth rates.

Main Results:

• TRβ1 expression significantly inhibited breast cancer cell proliferation and invasion.
• cSrc-mediated phosphorylation of TRβ1 at Y406 signals T3-induced degradation; mutation to TRβ1Y406F blocked this degradation.
• TRβ1Y406F cells lost the tumor-suppressive effects observed with wild-type TRβ1.
• TRβ1Y406F exhibited increased association with cSrc, leading to constitutive activation of the cSrc-FAK-ERK pathway, whereas TRβ1 degradation attenuated this signaling.

Conclusions:

• TRβ1 acts as a tumor suppressor in breast cancer, with its T3-induced degradation being a key mechanism.
• The phosphorylation status at Y406 and subsequent degradation of TRβ1 by cSrc are critical for its anti-proliferative and anti-invasive effects.
• TRβ1 represents a potential novel therapeutic target for breast cancer treatment.